Replimune reports ~$466M cash, runway into 2H 2026; updates RP1/RP2 clinical data

Replimune Group, Inc.

Preliminary cash and equivalents of ~$466M as of Dec 31, 2023; funds operations into second half of 2026.
Updated clinical data for RP1 and RP2 presented at 42nd J.P. Morgan Healthcare Conference.
Cash estimate is unaudited, subject to completion of quarterly closing procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.